This Immune Cell Could Promote Healthy Hair Growth – Science World Report


Science World Report
This Immune Cell Could Promote Healthy Hair Growth
Science World Report
On the other hand, the researchers discovered that when you knock this immune cell known as Tregs, the hair will not grow anymore. Professor Rosenblum said that it is as if the skin stem cells and Tregs have co-evolved so that the Tregs not only guard ...
Hair Growth Discovery Could Help Develop A Treatment For Hair LossIFLScience

all 16 news articles »

Read more:
This Immune Cell Could Promote Healthy Hair Growth - Science World Report

Seed Funding for a German Cell Therapy to Prevent Transplant … – Labiotech.eu (blog)

TolerogenixX has proved that it can get rid of immunosuppressants in organ transplants in Phase I and secured seed funding from High-Tech Grnderfonds.

TolerogenixXis a startup from the Heidelberg University Hospital that developspersonalized immunosuppression therapies. Its cell therapy technology has just passed Phase I, where it showed an impressive efficacy in preventing the rejection of kidney transplants without the need for immunosuppressive drugs.

The promising results seemto have convinced the German life sciences investorHigh-Tech Grnderfonds (HTGF),from which TolerogenixX has secured seed funding. HTGF is the first investor to jump in after pre-seed financing from the German Government. The funds, of an undisclosedamount, will help the startup make the preparations for a Phase II trial, planned for spring 2018.

TolerogenixXstechnology provides individualized immunosuppression, tailored specifically to the donor tissue. To do so,peripheral blood mononuclear cells (PBMCs) are harvested from the donor and treated with mitomycinCand then infused into the patient prior to the transplant.

Researchers at the University of Heidelberg discovered that mitomycin C inducesa change of behavior in dendritic cells, leading them to suppressT-cell responses. Immunological tests conducted during the trial revealed that the recipients had developed tolerance towards the donor.

The TolerogenixX technique represents a milestone in the field of individualized immunosuppression, saidPhilipp Rittershaus, Investment Manager at HTGF. Indeed, the therapy would allow transplantation without the need for immunosuppressants, which carry many severe side effects and leave patients completely unprotected against infections.

If everything goes well,TolerogenixX expects to complete Phase III andfile for approval in 2022. In addition, it will start a second program next year to treat autoimmune diseases such as multiple sclerosis and systemic lupus erythematosus. The methodology would be very similar, just using autologous cells instead for the mitomycin C treatment instead of donor cells.

This is a real quantum leap in the treatment of transplant patients, said in a statement Matthias Schaier, CEO of TolerogenixX. In the future, it will no longer be necessary to take various medications with numerous side effects.

Images via crystal light / Shutterstock;TolerogenixX

Read the original post:
Seed Funding for a German Cell Therapy to Prevent Transplant ... - Labiotech.eu (blog)

Donor appeal as baby Austin Brown awaits stem cell treatment – Kent Online

A six-month-old boy with a one-in-a-million blood disorder has found the match he needed for a potentially life-saving stem cell transplant.

Austin Brown was born with Wiskott-Aldrich syndrome and is being treated at Great Ormond Hospital with regular blood transfusions.

But until recently his family still needed to find a healthy person with the same tissue type willing to help replace and repair his damaged cells.

Parents Lewis and Kasia, of Lower Higham Road, Gravesend, enlisted the help of blood cancer charity Anthony Nolan to find a suitable donor.

Austin is half Polish, and his donor is most likely to have a similar background to him, said Mr Brown.

The details of what happens next are being worked out but in the meantime the family is calling for other people to help those in need.

Mr Brown added: My wife and I are calling on everyone to please join the Anthony Nolan register.

You will have an eternally grateful father and mother for the remainder of your life.

The family finally found a donor this week. Mr Brown couldnt be a donor for his son because he has epilepsy, but has been doing his bit by putting on events to raise awareness of Anthony Nolans work.

On Monday, June 19, he will play 72 holes of golf in one day at Deangate Ridge Golf & Sports Complex.

He hopes it will be the first of many events to raise both awareness and money for the charity.

He continued: Austin is full of beans. You would never know, to look at him, theres anything wrong with him. Hes nearly crawling.

When he reaches milestones like that and you share little moments as a family its truly like a ray of sunshine.

Money raised for Anthony Nolan funds research to make bone marrow and blood stem cell transplants more successful, pays for donors to be tissue-typed, and gathers vital information for patients and families in need.

The charity was named after a boy of the same name who died from the same condition that Austin has back in 1971.

It was set up by his mother after the difficulty she had in finding a suitable donor.

If you are aged between 16 and 30, you can join the charitys register online at anthonynolan.org.

To donate to Mr Browns campaign, visit the family's JustGiving site.

More:
Donor appeal as baby Austin Brown awaits stem cell treatment - Kent Online

Stem Cell Research at Johns Hopkins Medicine: Spinal …

John W. McDonald, M.D., Ph.D. an associate professor of neurology at the Johns Hopkins University School of Medicine and director of the International Center for Spinal Cord Injury at Kennedy Krieger Institute taps into the bodys own repair mechanisms in search of treatments for spine injury.

Stem cells allow us to address questions Ive thought about forever. These are really exciting times for the repair of the nervous system, because we can move beyond mere correlation and get definitive answers.

Despite what I was taught in medical school, nervous system cells do divide and grow. Not all of them. But oligodendrocytes are the most prominent ones that do. If we were to follow newly born cells in an adult human brain for an hour, the majority of those cells would go on to become oligodendrocytes.

Injury and the consequence of injury disrupts the turning over of cells, basically because of reduced electrical activity, which oligodendrocytes depend on for survival and myelination.

Im convinced that endogenous stem cells in the spinal cordthose naturally born there by the million, every hour, even in spinal cord injured adultsrepresent an important therapeutic target.

Through the transplantation work were doing in mice, were learning a lot about the natural environment of cells in the nervous system. For example, mouse embryonic stem cells have the innate mechanism to overcome physical and chemical barriers. Their presence changes the microenvironment enough so that endogenous cells are able to cross barriers such as scars. We are working on figuring how to activate the same cues that cause those microenvironment changes without actually transplanting stem cells.

The whole nervous systemall the signaling between cellsruns by electrical activity. Were just now getting access to the imaging tools to be able to see and begin to understand it. If that ensemble of activity is disrupted by injury, what percent of connections remain, and how can we use what remains to recreate the orchestra?

New imaging methods now are confirming earlier animal studies that as much as 30 percent of connections can still remain below the level of spinal cord injury, even in the severe injury scenarios. This realizationthat we dont need to cure the nervous system, we just need partial repairis born out in people whove had bad spinal cord injuries who now can regain substantial function and even walk..

Our strategy is to maximize the physical integrity of your body so it can meet a cure halfway when a cure comes. We discovered that we can make a great impact on an individuals own spontaneous recovery by facilitating the bodys own micro-repair system.

What we do in lab is geared toward understanding these mechanisms of microrepair. We already know that myelination and birth of oligodendrocytes are incredibly dependent on electrical activity.

Our focus now is on figuring out how to empower a bodys own endogenous stem cells, and using embryonic stem cells as scientific tools of discovery.

--Interviewed by Maryalice Yakutchik

The rest is here:
Stem Cell Research at Johns Hopkins Medicine: Spinal ...

Thousands attend tour of bright, colorful Buffett Cancer Center – Omaha World-Herald

Before touring the Fred & Pamela Buffett Cancer Center on Saturday, Susie Swanson stopped to pose for a photo with her husband, Jim, and their 25-year-old daughter, Sadie.

She held a sign that read Im a cancer survivor.

The Swansons, who drove from Lincoln, were among the more than 2,000 people who toured the cancer center during an open house. Though impressed with the amazing facility, Susie Swanson, 64, said she hopes that she wont have to return more than once a year for her check-up.

She was diagnosed last June with multiple myeloma a cancer formed by malignant plasma cells. After chemotherapy and a stem cell transplant, her hair has grown back, and shes now on maintenance medication.

I dont want to have to come back here as a cancer patient, Susie Swanson said while walking through the new centers halls. Sadie smiled and replied, But if you do, you have an amazing building to come to.

Saturdays open house offered a chance for the public to see highlights of the $323 million cancer center, a joint venture between the University of Nebraska Medical Center and clinical partner Nebraska Medicine. Visitors admired the variety of art and got to peek inside research labs, waiting areas and the 24/7 treatment center. The center will open to patients June 5.

Theres been a lot of buzz around this project, said medical center spokesman Taylor Wilson. I think people were anxious to see if it was what we told them it would be. From what Ive heard, they are realizing its all they heard about and more.

Susie Swanson said the tour was worth the drive.

Its amazing to have everything a cancer patient might need under one roof, she said.

As the family walked through the Chihuly Sanctuary filled with installations by glass artist Dale Chihuly Sadie Swanson snapped photos, and her mom kept repeating, Wow.

Susie Swanson recalled when she was recovering from her stem cell transplant and her doctor flung open the blinds, saying, You cant get better in the dark.

This place is so cheerful, she said. Its so bright and colorful.

mara.klecker@owh.com, 402-444-1276

Follow this link:
Thousands attend tour of bright, colorful Buffett Cancer Center - Omaha World-Herald

A new method for creating safer induced pluripotent stem cells – Phys.Org

May 24, 2017 Journal cover image. Credit: Future Science Group

Induced pluripotent stem cells (IPSCs) hold great promise in regenerative medicine, personalized medicine and drug discovery. However, while avoiding the ethical controversies associated with embryonic stem cells, they carry neoplastic risk owing to the use of the oncogenes c-Myc and Lin28. This has limited their utility in the biomedical arena.

Work has previously demonstrated that IPSC generation can be uncoupled from c-Myc, but until now a viable oncogene- and virus-free method has proven elusive.

A new research article from Alan B Moy and colleagues at Cellular Engineering Technologies (IA, USA) and The John Paul II Medical Research Institute (IA, USA) describes a promising new IPSC reprogramming approach that attempts to solve these issues. The open access article, "Efficient method to create integration-free, virus-free, Myc and Lin28-free human induced pluripotent stem cells from adherent cells", is available in Future Science OA.

Their approach saw adherent fibroblasts reprogrammed using a combination of reprogramming molecules and episomal vectors. The combinatorial approach was successful, yielding colonies in which 100% expressed SSEA4.

"Our reprogramming method provides patient- and disease-specific IPSC[s] for drug discovery and personalized medicine applications with lower risk of oncogenic perturbations due to Lin28 and Myc", noted the authors. "The reprogramming method paves a pathway for autologous and allogeneic cell therapy that satisfies regulatory requirements."

The team anticipates that virus- and oncogene-free IPSCs could advance cell therapies, diagnostics and personalized medicine. Furthermore, they envision the technology helping to reduce clinical trial failure rates and improve drug development.

Explore further: Stem cell reprogramming factor controls change in cellular energy generation

More information: Anant Kamath et al, Efficient method to create integration-free, virus-free,and-free human induced pluripotent stem cells from adherent cells, Future Science OA (2017). DOI: 10.4155/fsoa-2017-0028

Provided by: Future Science Group

University of Tsukuba-led researchers explored the function of the reprogramming factor KLF4 in production of induced pluripotent stem cells (iPSCs). KLF4 was shown to bind upstream of the Tcl1 target gene, which controls ...

The potential to use a patient's own cells to treat non-healing chronic wounds - a serious complication of diabetes - took an important step forward as researchers successfully reprogrammed skin cells taken from diabetic ...

It's been more than 10 years since Japanese researchers Shinya Yamanaka, M.D., Ph.D., and his graduate student Kazutoshi Takahashi, Ph.D., developed the breakthrough technique to return any adult cell to its earliest stage ...

Researchers at the University of California, San Diego School of Medicine report a simple, easily reproducible RNA-based method of generating human induced pluripotent stem cells (iPSCs) in the August 1 edition of Cell Stem ...

How do you improve a Nobel Prize-winning discovery? Add a debilitating disease-causing gene mutation.

Scientists have discovered the gene essential for chemically reprogramming human amniotic stem cells into a more versatile state similar to embryonic stem cells, in research led by UCL and Heinrich Heine University.

There are significant gaps in our knowledge on the evolution of sex, according to a research review on sex chromosomes from Lund University in Sweden. Even after more than a century of study, researchers do not know enough ...

(Phys.org)Eusocial insects are predominantly dependent on chemosensory communication to coordinate social organization and define group membership. As the social complexity of a species increases, individual members require ...

Scientists using a high-resolution global climate model and historical observations of species distributions on the Northeast U.S. Shelf have found that commercially important species will continue to shift their distribution ...

If you open Google and start typing "Chinese cave gecko", the text will auto-populate to "Chinese cave gecko for sale" just US$150, with delivery. This extremely rare species is just one of an increasingly large number ...

Almost 150 years after Charles Darwin first proposed a little-known prediction from his theory of sexual selection, researchers have found that male moths with larger antennae are better at detecting female signals.

Plant scientists at the University of Cambridge have found a plant protein indispensable for communication early in the formation of symbiosis - the mutually beneficial relationship between plants and fungi. Symbiosis significantly ...

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Follow this link:
A new method for creating safer induced pluripotent stem cells - Phys.Org

Healing wounds with cell therapy – Medical Xpress

May 29, 2017

Diabetic patients frequently have lesions on their feet that are very difficult to heal due to poor blood circulation. In cases of serious non-healing infections, a decision to amputate could be made. A new therapeutic approach, presented recently in the Journal of Investigative Dermatology by Canadian researchers affiliated with the University of Montreal Hospital Research Centre (CRCHUM), could prevent these complications by promoting wound healing.

The solution isn't what you might expect, not just another antibiotic ointment or other prescription medication. It's the approach that's different, a way to heal through personalized medicine. "We discovered a way to modify specific white blood cells - the macrophages - and make them capable of accelerating cutaneous healing," explained nephrologist Jean-Franois Cailhier, a CRCHUM researcher and professor at the University of Montreal.

It has long been known that macrophages play a key role in the normal wound healing process. These white cells specialize in major cellular clean-up processes and are essential for tissue repair; they accelerate healing while maintaining a balance between inflammatory and anti-inflammatory reactions (pro-reparation).

"When a wound doesn't heal, it might be secondary to enhanced inflammation and not enough anti-inflammatory activity," explained Cailhier. "We discovered that macrophage behaviour can be controlled so as to tip the balance toward cell repair by means of a special protein called Milk Fat Globule Epidermal Growth Factor-8, or MFG-E8."

Cailhier's team first showed that when there is a skin lesion, MFG-E8 calls for an anti-inflammatory and pro-reparatory reaction in the macrophages. Without this protein, the lesions heal much more slowly. Then the researchers developed a treatment by adoptive cell transfer in order to amplify the healing process.

Adoptive cell transfer consists in treating the patient using his or her own cells, which are harvested, treated, then re-injected in order to exert their action on an organ. This immunotherapeutic strategy is usually used to treat various types of cancer. This is the first time it has been shown to also be useful in reprogramming cells to facilitate healing of the skin.

"We used stem cells derived from murine bone marrow to obtain macrophages, which we treated ex vivo with the MFG-E8 protein before re-injecting them into the mice, and we quickly noticed an acceleration of healing," said Dr. Patrick Laplante, Cailhier's research assistant and first author of the study.

Added Dr. Cailhier, "the MFG-E8 protein, by acting directly upon macrophages, can generate cells that will orchestrate accelerated cutaneous healing."

The beauty of this therapy is that the patient (in this case the mouse) is not exposed to the protein itself. Indeed, as Dr. Cailhier explained, "if we were to inject the MFG-E8 protein directly into the body there could be effects, distant from the wound, upon all the cells that are sensitive to MFG-E8, which could lead to excess repair of the skin causing aberrant scars named keloids. The major advantage [of this treatment] is that we only administer reprogrammed cells, and we find that they are capable of creating the environment needed to accelerate scar formation. We have indeed discovered the unbelievable potential of the macrophage to make healing possible by simple ex vivo treatment."

What now remains to be done is to test this personalized treatment using human cells. Thereafter, the goal will be to develop a program of human cell therapy for diabetic patients and for victims of severe burns. It will take several years of research before this stage can be reached.

This advanced personalized treatment could also make all the difference in treating cases of challenging wounds. According to the World Health Organization, diabetes affects 8.5% of the global population, and amputation rates of the lower extremities are 10 to 20 times higher in diabetics. "If, with this treatment, we can succeed in closing wounds and promoting healing of diabetic ulcers, we might be able to avoid amputations," Dr. Cailhier said.

"Serious burn victims could also benefit," he added. "By accelerating and streamlining the healing of burns, we may be able to reduce the infections and keloids that unfortunately develop much too often in such patients." Cancer patients requiring extensive reconstruction surgery could also benefit, he said.

Explore further: Macrophages need two signals to begin healing process

More information: Patrick Laplante et al, MFG-E8 Reprogramming of Macrophages Promotes Wound Healing by Increased bFGF Production and Fibroblast Functions, Journal of Investigative Dermatology (2017). DOI: 10.1016/j.jid.2017.04.030

Journal reference: Journal of Investigative Dermatology

Provided by: University of Montreal Hospital Research Centre (CRCHUM)

In the immune system, macrophages act not only as soldiers responding to invading pathogens but also help rebuild the injured tissue once the infection is defeated. A new study by Yale Medical School researchers published ...

Stem cell researchers at the University of Calgary have found another piece of the puzzle behind what may contribute to hair loss and prevent wounds from healing normally.

(Medical Xpress)The University of Queensland researchers have successfully restored wound healing in a model of diabetes paving the way for new treatments for chronic wounds.

University of Notre Dame researchers have discovered a compound that accelerates diabetic wound healing, which may open the door to new treatment strategies. Non-healing chronic wounds are a major complication of diabetes, ...

Johns Hopkins researchers, working with elderly mice, have determined that combining gene therapy with an extra boost of the same stem cells the body already uses to repair itself leads to faster healing of burns and greater ...

Research led by scientists in Dr. Song Hong's group at LSU Health New Orleans has identified a novel family of chemical mediators that rescue the reparative functions of macrophages (a main type of mature white blood cells) ...

Diabetic patients frequently have lesions on their feet that are very difficult to heal due to poor blood circulation. In cases of serious non-healing infections, a decision to amputate could be made. A new therapeutic approach, ...

Changing the natural electrical signaling that exists in cells outside the nervous system can improve resistance to life-threatening bacterial infections, according to new research from Tufts University biologists. The researchers ...

Obesity, already a global epidemic, is on the rise. Over one third of the U.S. population is currently afflicted, according to the Centers for Disease Control and the monetary costs alone are approaching $150 billion dollars ...

In experiments in mice, UC San Francisco researchers have discovered that regulatory T cells (Tregs; pronounced "tee-regs"), a type of immune cell generally associated with controlling inflammation, directly trigger stem ...

(Medical Xpress)A team of researchers with the Icahn School of Medicine at Mount Sinai in New York has found that giving a certain antibody to menopausal mice resulted in less weight gain and reduced bone loss. In their ...

A new study has uncovered a molecular mechanism in the prion protein, a protein responsible for neurodegenerative diseases, which may explain why nerve cells degenerate in these disorders.

Adjust slider to filter visible comments by rank

Display comments: newest first

I am very slow getting around. I am now 52 years old. I am forgetful at times and have difficulty expressing myself. I have difficulty swallowing at times. I become tired easily, I also become quite dizzy when performing any athletic function (jogging). I was on Levodopa/Carbidopa, 100/25. nothing was really working to help my condition. Finally i started on parkinson's herbal formula i purchased from Health Herbal Clinic, i read alot of great reviews from other patients who used the parkinson's herbal treatment. I used the herbal remedy for 7 weeks, its effects on parkinson's is amazing, all My symptoms gradually faded away, I have been active and hope to continue! (Visit www. healthherbalclinic. weebly. com or email at healthherbalclinic@ gmail. com) I recommend this Parkinson's herbal formula for all Parkinson's Patients.

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

More here:
Healing wounds with cell therapy - Medical Xpress

Cheyenne Mountain Zoo makes medical history with ‘giraffe sneakers,’ stem cell treatments – Colorado Springs Gazette

Twiga, a 14-year-old female giraffe with advanced arthritis and osteoporosis in her feet, was fitted with custom shoes. (Photo courtesy of the Cheyenne Mountain Zoo.)

Cheyenne Mountain Zoo appears to have made medical history with its innovative giraffe treatments.

Mahali, a 14-year-old male giraffe who suffered from chronic lameness, is believed to be the first in the world to be injected with stem cells grown from giraffe blood, according to a news release from the zoo.

Stem cell therapy was chosen in the treatments led by Dr. Liza Dadone, the zoo's head veterinarian, because it has proven to repair damaged tissue. Staff at Colorado State University's James L. Voss Veterinary Teaching Hospital in Fort Collins helped with the treatment.

Nearly a month after the procedure, when Mahali was injected with about 100 million stem cells, thermographic images of the giraffe's front legs show "a considerable decline" in inflammation in his front left leg, the leg that had been giving him trouble, the zoo said.

"This is meaningful to us not only because it is the first time a giraffe has been treated with stem cells, but especially because it is bringing Mahali some arthritis relief and could help other giraffes in the near future," Dadone said in a written statement.

Dadone said it's not clear whether the successful results are due only to the stem cell treatment or a combination of treatments.

"Prior to the procedure, he was favoring his left front leg and would lift that foot off the ground almost once per minute," she said in the statement. "During the immobilization, we did multiple treatments that included hoof trims, stem cell therapy and other medications. "Since then, Mahali is no longer constantly lifting his left front leg off the ground and has resumed cooperating for hoof care. A few weeks ago, he returned to life with his herd, including yard access. On the thermogram, the marked inflammation up the leg has mostly resolved."

Twiga, a 14-year-old female giraffe with advanced arthritis and osteoporosis in her feet, was fitted with custom shoes with the help of farriers Steve Foxworth and Chris Niclas of the Equine Lameness Prevention Organization.

"We've had Twiga on medicine to help reverse her osteoporosis, but we wanted to do more to protect her feet. So with the help of the farriers, we gave her 'giraffe sneakers' to help give her some extra cushion," Dadone said in a written statement.

The giraffe's behavior was immediately changed - "Twiga instantly shifted her weight off of her right foot, indicating she was comfortable and her pain had considerably lessened" - but she will likely wear the shoes for about six more weeks, the zoo said.

Giraffes' size can make them more susceptible to issues like arthritis and osteoporosis. "Like all animals, these issues are exacerbated as they age," according to the zoo news release.

The zoo has a herd of 17 giraffes, including a newborn in April. The calf, a girl, was the 199th to be born in the 63-year history of the zoo's breeding program.

Giraffes' status was recently changed from "least concern" to "vulnerable" by the International Union for Conservation of Nature because the population in the wild has decreased by 40 percent in the last 30 years, the zoo said.

-

Contact Ellie Mulder: 636-0198

Twitter: @lemarie

Continued here:
Cheyenne Mountain Zoo makes medical history with 'giraffe sneakers,' stem cell treatments - Colorado Springs Gazette

Role of Stem Cells in Chronic Lung Diseases Revealed – Technology Networks

A novel population of lung stem cells plays an important role in regulating the pulmonary microvasculature the network of tiny blood vessels where oxygen and carbon dioxide exchange takes place.

The stem cells, called mesenchymal progenitor cells (MPCs), likely contribute to the pathobiology of chronic lung diseases, said Susan Majka, Ph.D., associate professor of Medicine.

Understanding the normal function and disease-associated dysfunction of MPCs could lead to earlier diagnosis and improved treatment for diseases such as pulmonary fibrosis, emphysema and pulmonary hypertension. The findings were reported this month in the Journal of Clinical Investigation.

Chronic lung diseases are marked by changes in lung tissue structure that include remodeling and loss of microvessels. The loss of microvessels impairs gas exchange, causing shortness of breath.

The vascular remodeling had been attributed to the endothelial cells that line blood vessels or the smooth muscle cells that surround them, Majka said. But endothelial and smooth muscle cells are terminally differentiated they are not likely to become other types of cells and Majka believed that unidentified stem cells, which can produce multiple types of mature cells with varied functions, were more likely to underlie tissue remodeling.

She and her colleagues had isolated vascular stem cells from mouse and human lungs and characterized them as MPCs that are located next to the microvasculature in the adult tissue. Now, they have used novel advanced lineage mapping tools to track the cells, under normal conditions and when signaling pathways associated with adult lung diseases are activated (Wnt signaling) or reduced (BMPR2 signaling).

When these cells are abnormal, animals develop vasculopathy a loss of structure in the microvessels and subsequently the lung. They lose the surfaces for gas exchange, Majka said.

The investigators also followed the cells after lung injury experimentally induced fibrosis (scarring). They discovered that the MPCs, which are abnormally activated after injury, formed an adaptive vascular structure that had never been previously characterized.

It appears to be a form of vascular mimicry, tubular structures that will circulate blood but are not normal blood vessels, Majka said. Its a new form of angiogenesis that could get blood into the middle of fibrotic areas, but our studies ended early after the injury, during peak fibrosis, and we dont know yet if its helping repair the injury or is actually detrimental.

Majka and her colleagues also used human lung tissues obtained from transplant or other surgeries to isolate MPCs. They compared human and mouse MPCs from normal and diseased lung tissue and showed that the cells have similar characteristics and gene expression profiles, defining the work as relevant to human disease.

Its very exciting to discover something new like this cell type that is so important in maintaining microvascular and lung tissue structure and that has potential implications in disease and repair, Majka said.

Understanding the MPCs, and other cell populations in the lung, is important for efforts to use stem cells to repair injured lung tissues, or to build lung tissue grafts.

Its critical to understand how different cells in the lung microenvironment regulate each other, and we really dont know that yet, Majka said.

By studying gene expression patterns in MPCs from normal and diseased or injured lungs, Majka and her colleagues have discovered new targets that may point to biomarkers for earlier detection of pulmonary diseases and that may guide the development of interventions that promote repair.

With pulmonary vascular diseases, by the time a patient has symptoms, theres already major damage to the microvasculature, Majka said. Using new biomarkers to detect the disease before symptoms arise would allow for earlier treatment, which could be effective at decreasing progression or even reversing the disease process.

In addition, MPCs are present in many adult tissues, including skin, kidney and uterus, suggesting that the findings may improve understanding of the microvascular basis of disease pathophysiology in these tissues.

This article has been republished frommaterialsprovided by Vanderbilt University Medical Center. Note: material may have been edited for length and content. For further information, please contact the cited source.

Reference:

Gaskill, C. F., Carrier, E. J., Kropski, J. A., Bloodworth, N. C., Menon, S., Foronjy, R. F., . . . Majka, S. M. (2017). Disruption of lineage specification in adult pulmonary mesenchymal progenitor cells promotes microvascular dysfunction. Journal of Clinical Investigation. doi:10.1172/jci88629

Link:
Role of Stem Cells in Chronic Lung Diseases Revealed - Technology Networks

Adaptimmune Therapeutics (ADAP) Begins Study to Evaluate … – StreetInsider.com

Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.

Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it has initiated its study of NY-ESO SPEAR Tcells targeting NY-ESO in combination with KEYTRUDA (pembrolizumab), an anti-PD-1 inhibitor marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the US and Canada), in patients with multiple myeloma. This study is now open for enrollment.

This is Adaptimmunes third clinical trial to initiate within the past month. The Company recently announced the initiation of clinical studies with its wholly-owned SPEAR T-cells targeting AFP in hepatocellular carcinoma, as well as its wholly-owned SPEAR T-cells targeting MAGE-A4 in seven malignant solid tumors.

We are excited to initiate this study as we have already seen encouraging data in a previous singleagent study of NYESO SPEAR T-cells in patients with advanced myeloma in the context of stem cell transplantation, said Rafael Amado, Adaptimmunes Chief Medical Officer. KEYTRUDA has also shown preliminary evidence of activity in multiple myeloma in combination, and there is preclinical evidence to support the view that the combination of NY-ESO SPEAR T-cells and anti-PD-1 therapy may lead to meaningful antitumor activity.

This is an open-label, randomized pilot study designed to evaluate the safety and anti-tumor activity of Adaptimmunes NY-ESO therapeutic candidate alone or in combination with KEYTRUDA in patients who are HLA-A*02 positive and have relapsed and refractory multiple myeloma expressing NY-ESO-1 and/or LAGE1a. The study will enroll up to 20 patients. The primary objective of the study is to evaluate the safety and tolerability of NY-ESO SPEAR T-cell therapy alone or in combination with KEYTRUDA. Additional objectives include antitumor activity, persistence of genetically modified cells in the body, and evaluation of the phenotype and functionality of genetically modified cells isolated from peripheral blood or tumor post infusion.

Adaptimmune is developing the NY-ESO SPEAR T-cell program under a strategic collaboration agreement with GSK.

Clinical Trial Collaboration Agreement for use of KEYTRUDA

Adaptimmune has a clinical trial collaboration agreement with Merck & Co., Inc., Kenilworth, NJ, USA for the use of KEYTRUDA in this study. The agreement is between Adaptimmune and Merck & Co., Inc., Kenilworth, NJ, USA, through a subsidiary. Under the agreement, the trial will be sponsored by Adaptimmune. The agreement also includes provision for potential expansion to include Phase III registration studies in the same indication. Additional details were not disclosed.

KEYTRUDA is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Visit link:
Adaptimmune Therapeutics (ADAP) Begins Study to Evaluate ... - StreetInsider.com